Welcome in CFDB (Cystic Fibrosis DataBase)!
This is a web-based, free access tool for health care professionals, researchers and students to evaluate in real time what are the current evidences about clinical efficacy of interventions in CF.
You'll find more than 1,300 studies divided in 8 sections, including Cochrane reviews, Cochrane protocols, DARE, HTA and Economic reviews, published RCT, published non-RCT, congress abstracts and ongoing trials.
Objective of CFDB (Cystic Fibrosis DataBase)
CFDB is a database and was ideated to classify clinical studies to get answers to specific questions:
- which interventions are effective, in which groups of CF patients and for which outcomes?
- to what extent do the results of the literature allow to make decisions for specific clinical issues? What issues need to be studied further?
This tool may help clinicians, researchers, students to have a faster updated view of clinical research in CF by using queries on the main topics in CF care. It could also be helpful to anyone going to design new studies, as it provides a concise description of what is currently known and what issues, on the contrast, need additional research.
Latest articles
Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis
Cochrane Database of Systematic Reviews - Cochrane Review
Details- 2025
- Hurley Matthew N
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
primary studies published RCT
Details- 2024
- Keating C
Respiratory Outcomes and Aspergillus Serology Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis and a History of Aspergillus fumigatus Infection.
primary studies published, non RCT
Details- 2025
- Lanfranchi C
A Phase IIb, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Subjects with Cystic Fibrosis Aged 18 Years or Older (CHOICES)
ongoing trials trial from other registries
Details- 2024
A Phase 3, Open-label Study Evaluating the Long term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 12 Months of Age and Older
ongoing trials trial from other registries
Details- 2024
A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutaneous administration of anakinra in patients with cystic fibrosis (ANAKIN)"
ongoing trials trial from other registries
Details- 2024
A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX 121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age (VX21-121-105)
ongoing trials trial from other registries
Details- 2024